The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
31-May-22
$177 million
Target:
TherapeuticsMD, Inc.
Acquiror:
EW Healthcare Partners
Advised TherapeuticsMD, an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women, on the acquisition by an affiliate of EW Healthcare Partners, a private equity firm focused on making a growth equity investment in fast-growing healthcare companies
23-May-22
$220 million
Target:
Greenbacker Group LLC
Acquiror:
Greenbacker Renewable Energy Company
Advised the Special Committee on the acquisition of the management function currently being performed by Greenbacker Capital Management, an SEC-registered investment adviser, and certain affiliated companies into GREC’s wholly-owned subsidiary, Greenbacker Renewable Energy Corporation. As a result of the Acquisition, Greenbacker will operate as a fully integrated and internally managed company with its own internal executive management team and other employees to manage its business and operations
05-May-22
Undisclosed
Target:
Airtower Networks
Acquiror:
DIF Capital Partners
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
19-Apr-22
Pending
$107 million
Target:
Syrah Resources
Acquiror:
U.S. Department of Energy
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
01-Apr-22
$203 million
Target:
Monument Pipeline LP
Acquiror:
ARM Energy Holdings
Advised ARM Energy Holdings, an integrated North American energy services platform, on its acquisition and financing of Monument Pipeline LP, a Houston-based natural gas pipeline, from NextEra Energy Partners in a bilateral transaction
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
01-Feb-22
Undisclosed
Target:
Alteon Health
Acquiror:
U.S. Acute Care Solutions
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
28-Jan-22
Undisclosed
Target:
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Acquiror:
Laboratoires Théa SAS
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
22-Nov-21
$480 million
Target:
Goodrich Petroleum Corporation
Acquiror:
Paloma Resources LLC
Acted as sole advisor to Paloma Resources, a Houston based, privately held exploration and production company backed by EnCap Investments, on the acquisition of Goodrich Petroleum, a publicly listed (NYSE:GDP) exploration and production company, via a cash tender offer
21-Oct-21
~$9 billion
Target:
EagleClaw Midstream
Acquiror:
Altus Midstream
Advised EagleClaw Midstream, a leading midstream operator in the Permian Delaware basin, on an all-stock combination with Altus Midstream
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
20-Sep-21
Undisclosed
Target:
Faes Farma, flagship product Bilastine
Acquiror:
Hikma Specialty USA INC
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
17-Sep-21
$750 million
Target:
MDC Texas Energy
Acquiror:
Maple Energy Holdings
Advised MDC Texas Energy in connection with its Chapter 11 bankruptcy and sale of substantially all of its oil and gas assets to Maple Energy Holdings pursuant to a plan of reorganization
08-Sep-21
Undisclosed
Target:
Hydrogen Technology & Energy Corporation (HTEC)
Acquiror:
I Squared Capital
Advising I Squared Capital, an independent global infrastructure investment manager, on its acquisition of a 35% equity interest in HTEC, a privately-held leader in the hydrogen energy transition
05-Aug-21
$2 billion
Target:
Score Media and Gaming, Inc.
Acquiror:
Penn National Gaming, Inc.
Advising the Board of Directors of Score Media and Gaming (“theScore”), a leading digital media and sports betting and technology company, regarding the acquisition of theScore by Penn National Gaming
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
26-Feb-21
$2.0 billion
Target:
MDLIVE
Acquiror:
Cigna
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
20-Jan-21
$1.9 billion
Target:
Extraction Oil and Gas
Acquiror:
N/A
Advised the Official Committee of Unsecured Creditors on the in-court restructuring of Extraction Oil and Gas, Inc., an Exploration and Production company focused on the Wattenberg Field of the Denver-Julesburg Basin
31-Dec-20
$1.2 billion
Target:
Pacific Drilling
Acquiror:
N/A
Advised Pacific Drilling, an international provider of offshore drilling services, on its pre-arranged Chapter 11 restructuring
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization